Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651488 | 1.00 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15653074 | 1.00 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL13362034 | 0.91 | QDPR (0.54) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15651303 | 0.87 | PDE4B (0.48) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15653114 | 0.87 | PDE4B (0.48) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15652355 | 0.87 | PDE4B (0.48) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2227613 | 0.86 | QDPR (0.59) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3311407 | 0.86 | QDPR (0.74) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL13362111 | 0.82 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15652563 | 0.82 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | QDPR 3390/4885PDE4B 2062/4885PDE4A 2056/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | QDPR 2413/4885PDE4B 1237/4885PDE4A 1139/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | QDPR 3390/4885PDE4B 2062/4885PDE4A 2056/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | QDPR 3201/4885PDE4B 2301/4885PDE4A 2227/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | QDPR 3201/4885PDE4B 2301/4885PDE4A 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.